Trevi Therapeutics, Inc.
TRVI
$7.55
$0.060.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.42% | 25.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.63% | -6.31% | |||
| Operating Income | -19.63% | 6.31% | |||
| Income Before Tax | -19.04% | 9.19% | |||
| Income Tax Expenses | -90.91% | -168.75% | |||
| Earnings from Continuing Operations | -18.97% | 9.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.97% | 9.42% | |||
| EBIT | -19.63% | 6.31% | |||
| EBITDA | -19.69% | 6.33% | |||
| EPS Basic | -7.39% | 18.38% | |||
| Normalized Basic EPS | -7.45% | 18.15% | |||
| EPS Diluted | -7.39% | 18.38% | |||
| Normalized Diluted EPS | -7.45% | 18.15% | |||
| Average Basic Shares Outstanding | 10.83% | 10.94% | |||
| Average Diluted Shares Outstanding | 10.83% | 10.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||